- The data comes from a phase 2/3 study that included 2,268 participants ages 5-11.
- The trial participants received two 10-microgram doses of Pfizer’s COVID-19 vaccine, administered 21 days apart. For people ages 12 and older, Pfizer uses a 30-microgram dose.
- Pfizer said the trial demonstrated a “favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age.” The findings have not been peer reviewed or published in a scientific journal.
- Pfizer said it will share this data with the FDA and other regulators as soon as possible.
- Of the drugmakers with a COVID-19 vaccine in use in the U.S., Pfizer is the first one to produce results from a trial testing its vaccine in children ages 5 to 11.
Pfizer says its vaccine is safe & effective in 5-11 year-olds: 5 things to know
Pfizer on Sept. 20 released trial data showing its COVID-19 vaccine is safe and effective in children ages 5 to 11. Here are five key details:
Next Up in Pharmacy
-
A coalition of 39 state attorneys general called on Congress to pass legislation prohibiting pharmacy benefit managers and parent companies…
-
The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in…
-
Commonly prescribed medications such as statins, non-steroidal anti-inflammatory drugs and certain blood pressure drugs may significantly delay the onset of…
Comments are closed.